Background: Methodological problems of existing research, such as the application of unstandardized treatments in heterogeneous samples, has hampered clear conclusions about the extent and direction to which allelic variation of the serotonin transporter gene-linked polymorphic region (5- HTTLPR) is associated with a differential response to psychological treatment. The present study aimed to investigate the effects of the 5-HTTLPR genotype on treatment outcome under highly standardized environmental conditions. Methods: We treated 222 medication-free adults highly fearful of spiders, dental surgeries or blood, injuries and injections with a highly standardized exposure-based 1-session treatment and genotyped them for the 5-HTTLPR. Participants' subjective fear was assessed before, immediately after treatment and at 7 months of follow-up. Results: There were no differences between 5-HTTLPR genotypes in treatment outcome effects at the immediate posttreatment assessment. However, we observed a highly significant genotype × treatment effect (p = 0.004) at the 7-month follow-up. Fear levels of homozygous S allele carriers differed from those heterozygous (p = 0.026) and homozygous (p = 0.012) for the L allele. Compared to posttreatment assessment, LL allele carriers exhibited a further fear decrease at the follow-up assessment. In contrast, SS allele carriers displayed a strong return of fear. Conclusions: Results suggest that genetic variation of the serotonin transporter is associated with differential stability of inhibitory learning processes, potentially reflecting heightened susceptibility for context-related processes that facilitate a return of fear in S allele carriers. If replicated, results suggest the 5-HTTLPR might represent a biomarker for the long-term outcome of brief exposure-based fear treatments and might inform genotype-based selection of psychotherapeutic interventions.

1.
Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE: Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010;167:509-527.
2.
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389.
3.
Karg K, Burmeister M, Shedden K, Sen S: The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011;68:444-454.
4.
Sharpley CF, Palanisamy SK, Glyde NS, Dillingham PW, Agnew LL: An update on the interaction between the serotonin transporter promoter variant (5-HTTLPR), stress and depression, plus an exploration of non-confirming findings. Behav Brain Res 2014;273:89-105.
5.
Culverhouse RC, Saccone NL, Horton AC, Ma Y, Anstey KJ, Banaschewski T, et al: Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5- HTTLPR genotype contributing to the development of depression. Mol Psychiatry 2017, Epub ahead of print.
6.
Murphy SE, Norbury R, Godlewska BR, Cowen PJ, Mannie ZM., Harmer CJ, Munafo MR: The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Mol Psychiatry 2013;18:512-520.
7.
Miller R, Wankerl M, Stalder T, Kirschbaum C, Alexander N: The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: a meta-analysis. Mol Psychiatry 2013;18:1018-1024.
8.
Pezawas L, Meyer-Lindenberg A, Drabant EM, Verchinski BA, Munoz KE, Kolachana BS: 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-834.
9.
Costafreda SG, McCann P, Saker P, Cole JH, Cohen-Woods S, Farmer AE, Aitchison KJ, McGuffin P, Fu CH: Modulation of amygdala response and connectivity in depression by serotonin transporter polymorphism and diagnosis. J Affect Disord 2013;150:96-103.
10.
Munafò MR, Freimer NB, Ng W, Ophoff N, Veijola J, Miettunen J, Järvelin MR, Taanila A, Flint J: 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet 2009;150:271-281.
11.
Balestri M, Calati R, Serretti A, De Ronchi D: Genetic modulation of personality traits: a systematic review of the literature. Int Clin Psychopharmacol 2014;29:1-15.
12.
Tyrer P, Seivewright N, Ferguson B, Tyrer J: The general neurotic syndrome. Acta Psychiatr Scand 1992;85:201-206.
13.
Barlow DH, Sauer-Zavala S, Carl JR, Bullis JR, Ellard KK: The nature, diagnosis, and treatment of neuroticism: back to the future. Clin Psychol Sci 2010;2:344-365.
14.
Belsky J, Jonassaint CR, Pluess M, Stanton M, Brummett B, Williams R: Vulnerability genes or plasticity genes? Mol Psychiatry 2009;14:746-754.
15.
Taylor SE, Way BM, Welch WT, Hilmert CJ, Lehman BJ, Eisenberger NI: Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology. Biol Psychol 2006;59:224-229.
16.
Lester KJ, Eley TC: Therapygenetics: using genetic markers to predict response to psychological treatment for mood and anxiety disorders. Biol Mood Anxiety Disord 2013;3:1-16.
17.
Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-293.
18.
Andersson E, Rück C, Lavebratt C, Hedman E, Schalling M, Lindefors N, Eriksson E, Carlbring P, Andersson G, Furmark T: Genetic polymorphisms in monoamine systems and outcome of cognitive behavior therapy for social anxiety disorder. PLoS One 2013;8: e79015.
19.
Bockting CLH, Mocking RJ, Lok A, Koeter MWJ, Schene AH: Therapygenetics: the 5HTTLPR as a biomarker for response to psychological therapy? Mol Psychiatry 2013;18:744-745.
20.
Bryant RA, Felmingham KL, Falconer EM, Benito LP, Dobson-Stone C, Pierce KD, Schofield PR: Preliminary evidence of the short allele of the serotonin transporter gene predicting poor response to cognitive behavior therapy in posttraumatic stress disorder. Biol Psychiatry 2010;67:1217-1219.
21.
Eley TC, Hudson JL, Creswell C, Tropeano M, Lester KJ, Cooper P, Farmer A, Lewis CM, Lyneham HJ, Rapee RM, Uher R, Zavos HMS, Collier DA: Therapygenetics: the 5HTTLPR and response to psychological therapy. Mol Psychiatry 2012;17:236-237.
22.
Furmark T, Carlbring P, Hammer S, Wahlgren I, Ekselius L, Eriksson E, Andersson G: Effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on the response to cognitive-behavior therapy in individuals with social anxiety disorder. Biol Psychiatry 2010;67:1S-271S.
23.
Hedman E, Andersson E, Ljótsson B, Andersson G, Schalling M, Lindefors N, Rück C: Clinical and genetic outcome determinants of Internet- and group-based cognitive behavior therapy for social anxiety disorder. Acta Psychiatr Scand 2012;2:126-136.
24.
Knuts I, Esquivel G, Kenis G, Overbeek T, Leibold N, Goossens L, Schruers K: Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia. Eur Neuropsychopharmacol 2014;24:1222-1228.
25.
Kohen R, Cain KC, Buzaitis A, Johnson V, Becker KJ, Teri L, Tirschwell DL, Veith RC, Mitchell PH: Response to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphisms. Stroke 2011;42:2068-2070.
26.
Lester KJ, Roberts S, Keers R, Coleman JRI, Breen G, Wong CCY, Xiaohui Xu, Arendt K, Blatter-Meunier J, Bögels S, Cooper P, Creswell C, Heiervang ER, Herren C, Hogendoorn SM, Hudson JL, Krause K, Lyneham HJ, McKinnon A, Morris T, Nauta MH, Rapee RM, Rey Y, Schneider S, Schneider SC, Silverman WK, Smith P, Thastum M, Thirlwall K, Waite P, Wergeland GJ, Eley TC: Non-replication of the association between 5HTTLPR and response to psychological therapy for child anxiety disorders. Br J Psychiatry 2016;208:182-188.
27.
Lonsdorf TB, Rück C, Bergström J, Andersson G, Öhman A, Lindefors N, Schalling M: The COMTval158met polymorphism is associated with symptom relief during exposure-based cognitive-behavioral treatment in panic disorder. BMC Psychiatry 2010;10:99.
28.
Sakolsky D, Nurmi E, Birmaher B, March JS, Walkup J, Piacentini J, et al: Serotonin Transporter Variation and Treatment Response in the Child/Adolescent Anxiety Multimodal Study (CAMS). Toronto, American Academy of Child and Adolescent Psychiatry, 2011.
29.
Wang Z, Harrer J, Tuerk P, Acierno R, Hamner M, Timmerman MA, Abbott T: 5-HTTLPR influence PTSD treatment outcome. 64th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry, Vancouver, 2009.
30.
Fava, G, Giudi J, Grandi S, Hasler G: The missing link between clinical states and biomarkers in mental disorders. Psychother Psychosom 2014;83:136-141.
31.
Beevers CG, McGeary JE: Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci 2011;16:11-12.
32.
Wannemueller A, Appelbaum D, Küppers M, Matten A, Teismann T, Adolph D, Margraf J: Large group exposure treatment: a feasibility study in highly spider fearful individuals. Front Psychol 2015;7:1183.
33.
Wannemueller A, Jöhren HP, Borgstädt A, Bosch J, Meyers M, Völse M, Scholten S, Margraf J: Large group exposure treatment: a feasibility study of exposure combined with diaphragmatic breathing in highly dental fearful individuals. Front Psychol 2017;7:2007.
34.
Öst LG: One-session treatment for specific phobias. Behav Res Ther 1989;27:1-7.
35.
Rinck M, Bundschuh S, Engler S, Müller A, Wissmann J, Ellwart T, Becker ES: Reliabilität und Validität dreier Instrumente zur Messung von Angst vor Spinnen. Diagnostica 2002;48:141-149.
36.
Corah NL: Development of a dental anxiety scale. J Dent Res 1969;48:596-602.
37.
Vossbeck-Elsebusch AN, Schroers LK, Gerlach AL: Diagnostik der Blut-Verletzungs-Spritzen-Angst Entwicklung und Validierung eines Erhebungsinstrumentes. Z Klin Psychol Psychother 2011;41:47-56.
38.
Spielberger CD, Gorsuch RL, Lushene RE: Manual of the State-Trait-Anxiety Inventory. Palo Alto, CPP Inc, 1970.
39.
Costa PT, McCrae RR: Revised NEO Personality Inventory (NEO-PIR) and NEO Five Factor Inventory (NEO-FFI) Professional Manual. Odessa, Psychological Assessment Resources, 1992.
40.
Hautzinger M, Bailer M, Worall H, Keller F: Beck-Depressions-Inventar (BDI). Bearbeitung der deutschen Ausgabe. Testhandbuch. Bern, Huber, 1994.
41.
Lovibond SH, Lovibond PF: Manual for the Depression Anxiety Stress Scales, ed 2. Sydney, Psychology Foundation, 1995.
42.
Wendland JR, Martin BJ, Kruse MR, Lesch KP, Murphy DL: Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 2006;11:224-226.
43.
Goldman N, Glei DA, Lin YH, Weinstein M: The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress Anxiety 2010;27:260-269.
44.
Steiger H, Joober R, Gauvin L, Bruce KR, Richardson J, Israel M, Anestin AS, Groleau P: Serotonin-system polymorphisms (5- HTTLPR and -1438G/A) and responses of patients with bulimic syndromes to multimodal treatments. J Clin Psychiatry 2008;69:1565-1571.
45.
Hermans D, Craske MG, Mineka S, Lovibond PF: Extinction in human fear conditioning. Biol Psychiatry 2006;60:361-368.
46.
Lonsdorf TB, Menz MM, Andreatta M, Fullana MA, Golkar A, Haaker J, Heitland I, Hermann A, Kuhn M, Kruse O, Drexler SM, Meulders A, Neesl F, Pittig A, Richter J, Römer, S, Shiban Y, Schmitz A, Straube B, Vervliet B, Wendt J, Baas JMP, Merz CJ: Don't fear “fear conditioning”: methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fear. Neurosci Biobehav Rev 2017;77:247-258.
47.
Vervliet B, Craske MG, Hermans D: Fear extinction and relapse: state of the art. Annu Rev Clin Psychol 2013;9:215-248.
48.
Bouton ME: Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychol Bull 1993;114:80-99.
49.
Miller RR, Matzel LD: Contingency and relative associative strength; in Klein SB, Mowrer RR (eds): Contemporary Learning Theories: Pavlovian Conditioning and the Status of Traditional Learning Theory. Hillsdale, Erlbaum Associates, 1988, pp 61-84.
50.
Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B: Maximizing exposure therapy: an inhibitory learning approach. Behav Res Ther 2014;58:10-23.
51.
Baker A, Mystkowski J, Culver N, Yi R, Mortazavi A, Craske MG: Does habituation matter? Emotional processing theory and exposure therapy for acrophobia. Behav Res Ther 2010;48:1139-1143.
52.
Craske MG, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A: Optimizing exposure therapy for anxiety disorders: an inhibitory learning and inhibitory regulation approach. Verhaltenstherapie 2015;25:134-143.
53.
Quirk GJ: Memory for extinction of conditioned fear is long-lasting and persists following spontaneous recovery. Learn Mem 2002;9:402-407.
54.
Rescorla RA, Heth CD: Reinstatement of fear to an extinguished conditioned stimulus. J Exp Psychol Anim Behav Process 1975;1:88-96.
55.
Bouton ME, Bolles RC: Role of conditioned contextual stimuli in reinstatement of extinguished fear. J Exp Psychol Anim Behav Process 1979;5:368-378.
56.
Lonsdorf TB, Weike AI, Nikamo P, Schalling M, Hamm AO, Öhman A: Genetic gating of human fear learning and extinction. Psychol Sci 2009;20:198-206.
57.
Munafò MR, Brown SM, Hariri AR: Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry 2008;63:852-857.
58.
Bryant RA, Felmingham K, Kemp A, Das P, Hughes G, Peduto A, Williams L: Amygdala and ventral anterior cingulate activation predicts treatment response to cognitive behaviour therapy for post-traumatic stress disorder. Psychol Med 2008;38:555-561.
59.
Phelps EA, Delgado MR, Nearing KI, LeDoux JE: Extinction learning in humans: role of the amygdala and vmPFC. Neuron 2004;43:897-905.
60.
Quirk GJ, Russo GK, Barron JL, Lebron K: The role of ventromedial prefrontal cortex in the recovery of extinguished fear. J Neurosci 2000;20:6225-6231.
61.
Milad MR, Pitman RK, Ellis CB, Gold AL, Shin LM, Lasko NB, Zeidan MA, Handwerger K: Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry 2009;66:1075-1082.
62.
Wellman CL, Izquierdo A, Garrett JE, Martin KP, Carroll J, Millstein R, Lesch KP, Murphy DL, Holmes A: Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J Neurosci 2007;27:684-691.
63.
Narayanan V, Heiming RS, Jansen F, Lesting J, Sachser N, Pape HC, Seidenbecher T: Social defeat: impact on fear extinction and amygdala-prefrontal cortical theta synchrony in 5-HTT deficient mice. PLoS One 2011;6: e22600.
64.
Hartley CA, McKenna MC, Salman R, Holmes A, Casey BJ, Phelps EA, Glatt CE: Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory. Proc Natl Acad Sci USA 2012;109:5493-5498.
65.
Heinz A, Braus DF, Smolka MN, Wrase J, Puls I, Hermann D, Klein S, Grüsser SM, Flor H, Schumann G, Mann K, Büchel C: Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 2005;8:20-21.
66.
Milad MR, Wright CI, Orr SP, Pitman RK, Quirk GJ, Rauch SL: Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biol Psychiatry 2007;62:446-454.
67.
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL: Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-1531.
68.
Tobin RM, Graziano WG, Vanman EJ, Tassinary LG: Personality, emotional experience, and efforts to control emotions. J Pers Soc Psychol 2000;4:656-669.
69.
Haas BW, Omura K, Constable RT, Canli T: Is automatic emotion regulation associated with agreeableness? A perspective using a social neuroscience approach. Psychol Sci 2007;18:130-132.
70.
Öst LG, Alm, T, Brandberg M, Breitholtz E: One vs five sessions of exposure and five sessions of cognitive therapy in the treatment of claustrophobia. Behav Res Ther 2001;39:167-183.
71.
Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ: Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008;28:1021-1037.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.